BioNTech Posts $622.3M Loss in Q1 2026 as Oncology R&D Surges

BioNTech reported a net loss of $622.3 million in the first quarter of 2026, as revenue fell to $138.0 million and research and development expenses rose to $651.6 million. The company also announced a consolidation of its global manufacturing footprint, a share repurchase program of up to $1.0 billion, and reaffirmed full‑year 2026 revenue guidance of $2.3 to $2.6 billion.

Revenue declined from $213.8 million in the same period a year earlier, driven primarily by lower Covid‑19 vaccine sales. “Our revenues for the first quarter reflect the seasonal demand for Covid‑19 vaccines and are in line with our expectations,” the chief financial officer said. The net loss widened from $486.5 million a year ago, while the company maintained a strong cash position of $19.6 billion as of March 31.

Research and development expenses increased from $614.9 million to $651.6 million, reflecting higher spending on oncology and antibody‑drug conjugate programs, particularly pumitamig and gotistobart, as well as costs from entities acquired in 2025, including BioNTech China and CureVac.

BioNTech’s lead oncology program, pumitamig, a bispecific immunomodulator combining PD‑L1 checkpoint inhibition with VEGF‑A neutralization, advanced with five new pivotal trials initiated in the first quarter. These trials span first‑line triple‑negative breast cancer, microsatellite stable colorectal cancer, gastric cancer, and two non‑small cell lung cancer settings. Gotistobart, a CTLA‑4 targeting candidate, showed a clinically meaningful overall survival benefit in squamous NSCLC at the European Lung Cancer Congress in March, and interim data from the pivotal stage of its Phase III trial are expected later in 2026. “In the first quarter, we made substantial progress in executing towards our oncology strategy, highlighted by data presentations from our priority pan‑tumor program pumitamig as well as our versatile antibody‑drug conjugate portfolio,” the CEO said.

BioNTech plans to exit operations at manufacturing sites in Idar‑Oberstein and Marburg, Germany, by the end of 2027, and in Singapore by the first quarter of 2027. The consolidation is expected to generate approximately $584.9 million in recurring annual savings by 2029, which will be redirected toward advancing the oncology pipeline toward commercialization. Leadership changes are also underway, with the CEO and co‑founder expected to transition out of BioNTech by the end of 2026 to lead a new independent company focused on next‑generation mRNA innovations. The supervisory board is conducting an executive search for their successors.